Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Sarcoma 1Head & Neck 1Genitourinary 1Endocrine 1

Conditions

Prostatic Hyperplasia 1Multiple Endocrine Neoplasia Type 1 1Hyperplasia 1

Interventions

Docetaxel 390pembrolizumab 326Prednisone 285Gemcitabine 273enzalutamide 256Radiotherapy 251Nivolumab 248Magnetic Resonance Spectroscopy 247Cisplatin 209Abiraterone Acetate 198Radiosurgery 184Leuprolide 182Sunitinib 169Carboplatin 161bicalutamide 148Goserelin 145Androgen Antagonists 142Specimen Handling 138Ipilimumab 128Paclitaxel 125Cyclophosphamide 116acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 110Bevacizumab 109Everolimus 107apalutamide 99abiraterone 99cabozantinib 98atezolizumab 97Sorafenib 97Radiation 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Microspheres × Genitourinary × Clear all
NCT02167919 2017-09-14

Efficacy of Prostatic Artery Embolization (PAE) in Patients With Severe Benign Prostatic Hyperplasia (BPH)

University of North Carolina, Chapel Hill

Phase NA Completed
15 enrolled
EndocrineGenitourinary

Hyperplasia, Prostatic Hyperplasia, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡